MedTrace Logo

Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

NCT01558869 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2017-05-09

No results posted yet for this study

Summary

This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with advanced unresectable pancreatic carcinoma. Clinical data from patients diagnosed with pancreatic adenocarcinoma will be collected and analyzed in this study. The patients' data will be collected and maintained in the Division of Medical Oncology of the University Department of Medicine, Queen Mary Hospital, Hong Kong.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

Capecitabine

1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)

DRUG

Oxaliplatin

70 mg/m2 IV on day 1 of a 2-week cycle

DRUG

Irinotecan

130 mg/m2 IV on day 1 of a 2-week cycle

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Thomas Yau, MD · The University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01558869 on ClinicalTrials.gov